DANNCE.AI Secures $2.6M in Pre-Seed Funding to Advance Digital Phenotyping Platform
DANNCE.AI provides clinicians and drug developers with an AI-powered digital phenotyping platform designed to quantify and analyze movement and behavior in 3D.
Company Name: DANNCE.AI
Location: Boston, MA
Sector: Digital Phenotyping for Healthcare
Funding Details:
DANNCE.AI raised $2.6M in Pre-Seed funding led by:
- Lead Investor: LDV Capital
- Additional Participants: Glasswing Ventures, The Leo Lion Company, Duke Capital Partners, and Merck Digital Sciences Studio
Purpose of Funding:
The funds will be used to expand the company’s operations and accelerate development efforts of its AI-powered digital phenotyping platform.
Leadership:
- Rob Baldoni, CEO
- Dr. Tim Dunn, Co-founder & CSO
- Dr. Jesse Marshall, Co-founder & Advisor
About DANNCE.AI:
DANNCE.AI provides clinicians and drug developers with an AI-powered digital phenotyping platform designed to quantify and analyze movement and behavior in 3D. By leveraging videos from multiple cameras, its technology reconstructs movement and generates easy-to-interpret, quantified insights for use in:
- Diagnosis: Identifying and diagnosing movement impairments.
- Severity Assessment: Calculating the severity of impairments.
- Monitoring Progress: Tracking changes in patient movement over time.
How It Works:
DANNCE’s behavioral quantification workflow is built on markerless pose tracking, which replicates doctors’ assessments and uncovers clinical insights through the analysis of gross and fine movements.
Looking Ahead:
DANNCE.AI aims to revolutionize movement analysis, offering unprecedented precision and insight for clinicians and drug developers tackling movement-related conditions.